Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Ultragenyx Pharmaceutical Inc (RARE)  
$42.75 0.45 (1.04%) as of 4:30 Fri 5/3


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 82,110,000
Market Cap: 3.51(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $31.73 - $53.69
Level I Sector: Consumer Discretionary
Level II Sector: Leisure
Level III Sector: Restaurants

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ COMPOSITE
    NASDAQ INDUSTRIAL     S&P SMALLCAP 600
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co. has four commercially approved products, Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii® (vestronidase alfa) for the treatment of mucopolysaccharidosis VII, or Sly Syndrome, Dojolvi® (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders, and Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 69,133 99,133 200,384 249,340
Total Sell Value $3,373,178 $4,809,278 $8,291,909 $10,478,837
Total People Sold 8 8 9 12
Total Sell Transactions 10 11 20 34
End Date 2024-02-04 2023-11-03 2023-05-05 2022-05-05

   
Records found: 628
  Page 7 of 26  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Huizenga Theodore Alan SVP, Chief Accounting Officer   •       –      –    2021-05-06 4 S $113.67 $16,141 D/D (142) 15,031 16%     
   Harris Erik EVP & Chief Commercial Officer   •       –      –    2021-05-06 4 AS $113.68 $34,900 D/D (307) 27,110 -16%     
   Kassberg Thomas Richard CBO & EVP   •       –      –    2021-05-06 4 S $113.69 $41,269 D/D (363) 106,818 16%     
   Kakkis Emil D President & CEO   •       •      –    2021-05-06 4 D $115.71 $98,585 D/D (852) 595,200     -
   Parschauer Karah Herdman EVP and General Counsel   •       –      –    2021-05-06 4 S $113.67 $35,579 D/D (313) 29,997 16%     
   Bedrosian Camille L EVP and Chief Medical Officer   •       –      –    2021-05-06 4 S $113.67 $41,376 D/D (364) 38,775 16%     
   Kakkis Emil D President & CEO   •       •      –    2021-05-03 4 AS $107.80 $3,234,000 I/I (30,000) 2,259,741 -5%     
   Harris Erik EVP & Chief Commercial Officer   •       –      –    2021-04-20 4 AS $104.28 $41,295 D/D (396) 27,417 -11%     
   Huizenga Theodore Alan SVP, Chief Accounting Officer   •       –      –    2021-04-16 4 A $0.00 $0 D/D 1,500 15,044     -
   Bedrosian Camille L EVP and Chief Medical Officer   •       –      –    2021-04-15 4 AS $109.09 $545,450 D/D (5,000) 39,139 -20%     
   Bedrosian Camille L EVP and Chief Medical Officer   •       –      –    2021-04-15 4 OE $55.00 $275,000 D/D 5,000 44,139     -
   Huizenga Theodore Alan SVP, Controller and PAO   •       –      –    2021-03-08 4 S $120.69 $362,070 D/D (3,000) 13,544 26%     
   Harris Erik EVP & Chief Commercial Officer   •       –      –    2021-03-02 4 AS $138.16 $97,679 D/D (707) 27,813 -35%     
   Dier Mardi CFO & Executive Vice President   •       –      –    2021-03-01 4 A $0.00 $0 D/D 5,500 45,500     -
   Kakkis Emil D President & CEO   •       •      –    2021-03-01 4 AS $141.80 $4,254,000 I/I (30,000) 2,289,741 -36%     
   Kakkis Emil D President & CEO   •       •      –    2021-03-01 4 D $142.47 $2,328,245 D/D (16,342) 596,052     -
   Kakkis Emil D President & CEO   •       •      –    2021-03-01 4 A $0.00 $0 D/D 33,453 612,394     -
   Bedrosian Camille L EVP and Chief Medical Officer   •       –      –    2021-03-01 4 S $138.18 $627,752 D/D (4,543) 39,139 36%     
   Bedrosian Camille L EVP and Chief Medical Officer   •       –      –    2021-03-01 4 A $0.00 $0 D/D 10,136 43,682     -
   Huizenga Theodore Alan SVP, Controller and PAO   •       –      –    2021-03-01 4 S $138.17 $101,140 D/D (732) 16,544 36%     
   Huizenga Theodore Alan SVP, Controller and PAO   •       –      –    2021-03-01 4 A $0.00 $0 D/D 1,560 17,276     -
   Parschauer Karah Herdman EVP and General Counsel   •       –      –    2021-03-01 4 S $138.17 $548,535 D/D (3,970) 30,227 36%     
   Parschauer Karah Herdman EVP and General Counsel   •       –      –    2021-03-01 4 A $0.00 $0 D/D 10,136 34,197     -
   Kassberg Thomas Richard CBO & EVP   •       –      –    2021-03-01 4 S $138.17 $631,713 D/D (4,572) 107,181 36%     
   Kassberg Thomas Richard CBO & EVP   •       –      –    2021-03-01 4 A $0.00 $0 D/D 10,136 111,614     -
  628 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 7 of 26
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us